ELI-002 7P

DRUG3 trials

Sponsors

Elicio Therapeutics, Memorial Sloan Kettering Cancer Center

Conditions

Colorectal CancerKRAS G12AKRAS G12CKRAS G12DKRAS G12RKRAS G12SKRAS G12VKRAS G13D

Phase 1

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

Active, not recruitingNCT05726864

Elicio TherapeuticsColorectal Cancer, KRAS G12A, KRAS G12C +11

Start: 2023-04-14End: 2026-11-01Updated: 2026-07-10

A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

RecruitingNCT07671339

Memorial Sloan Kettering Cancer CenterPancreatic Cancer

Start: 2026-06-22End: 2028-06-01Target: 20Updated: 2026-06-26

Unknown Phase

Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma

Elicio TherapeuticsKRAS G12A, KRAS G12C, KRAS G12D +12

Updated: 2026-07-10

Related Papers

AMPLIFY-7P, a first-in-human safety and efficacy trial of adjuvant mKRAS-specific lymph node targeted amphiphile ELI-002 7P vaccine in patients with minimal residual disease–positive pancreatic and colorectal cancer.

Journal of Clinical Oncology2024-06-019 citations

Abstract CT107: Durable immunogenicity of ELI-002 2P in AMPLIFY-201: Lymph node targeted mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer

Cancer Research2024-04-051 citations

Abstract 4099: AMP-peptide vaccination against multiple p53 mutant epitopes promotes lymph node delivery to generate potent, functional T cell immunity

Cancer Research2024-03-22

AMPLIFY-7P: Phase 1 and randomized phase 2 study of amphiphile immunotherapy ELI-002 7P as adjuvant treatment for subjects with G12D, G12R, G12V, G12C, G12A, G12S and G13D Kirsten rat sarcoma (KRAS)-mutated pancreatic ductal adenocarcinoma.

Journal of Clinical Oncology2024-01-204 citations

Abstract C092: T cell responses and clinical outcomes in pancreatic and colorectal cancer patients with minimal residual disease in AMPLIFY-201, a phase 1 trial of a first-in-class amphiphile lymph node targeted mutant KRAS vaccine

Cancer Research2024-01-16

Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.

2024-01-09156 citations

656 ELI-002 immunotherapy induces broad polyfunctional T cell responses in subjects with high relapse risk KRAS mutated pancreatic ductal adenocarcinoma and colorectal cancer

Regular and Young Investigator Award Abstracts2023-10-311 citations

1145 A lymph node targeted AMP-peptide vaccine generates functional T cell immunity against mutant p53 and BRAF

Regular and Young Investigator Award Abstracts2023-10-31

AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D- or G12R-mutated pancreatic and colorectal cancer.

Journal of Clinical Oncology2023-06-0117 citations